% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Kreye:280960,
author = {Kreye, Jakob and Morgenlander, William R and Thakar,
Manjusha and Schulte-Frankenfeld, Poul M and Schott, Sarah
and Bünger, Isabel and Kornau, Hans-Christian and Angkeow,
Julia W and Jayaraman, Sahana and Otto, Carolin and Hahn,
Wiebke and Lewerenz, Jan and Thaler, Franziska S and
Korporal-Kuhnke, Mirjam and Melzer, Nico and Dargvainiene,
Justina and Bien, Christian G and Kohlie, Rose and Lattwein,
Erik and Schmitz, Dietmar and Calabresi, Peter A and Pardo,
Carlos A and Prüss, Harald and Ruprecht, Klemens and
Benjamin Larman, H.},
title = {{S}pecific viral antibodies associate with anti-{NMDAR}
encephalitis after herpes simplex encephalitis.},
journal = {Brain, behavior and immunity},
volume = {130},
issn = {0889-1591},
address = {Orlando, Fla. [u.a.]},
publisher = {Elsevier},
reportid = {DZNE-2025-01042},
pages = {106073},
year = {2025},
abstract = {Herpes simplex encephalitis (HSE) patients may develop
secondary anti-N-methyl-D-aspartate receptor (NMDAR)
encephalitis (NMDARE), associated with worsened long-term
neurological outcome. Immunosuppressive treatment can limit
NMDAR autoantibody-mediated pathology, but early predictive
biomarkers for the risk of NMDARE are lacking. In a
multicenter study, we performed unbiased antibody reactome
profiling using Phage ImmunoPrecipitation Sequencing
(PhIP-Seq). HSE patients with secondary NMDARE (n = 13)
versus those without (n = 10) showed enhanced antibody
responses against HSV-1, but not HSV-2, which comprised
specific antibodies to five peptides of the HSV-1 UL42 and
UL48 proteins. A score of these signature CSF antibodies
identified HSE patients with secondary NMDARE with a
sensitivity of $75\%,$ a specificity of > $99\%,$ a positive
predictive value of $90\%,$ a negative predictive value of >
$97\%$ and an odds ratio (OR) of 209 (CI: 28 - 1,582) across
all individuals in this study, and with similar performance
values in serum $(>66\%,$ $>99\%,$ $>88\%,$ $>96\%,$ OR 307
(15 - 6,089)). These signature antibodies represent a
promising biomarker to identify HSE patients at risk for
NMDARE development. In NMDARE patients without a history of
HSE and in MS patients, no disease-associated HSV antibody
reactivity patterns were detected. Furthermore, we
introduced the Multiplexed Index Calculations of the
Antibody Reactome (MICAR) metric to characterize proteomic
targets of compartment-specific antibody responses, an
approach that is applicable in neuroimmunology and other
compartmentalized disease states.},
keywords = {Antibody reactome (Other) / Encephalitis (Other) / HSE
(Other) / HSV (Other) / Intrathecal synthesis (Other) /
MICAR (Other) / NMDAR (Other) / PhIP-Seq (Other)},
cin = {AG Prüß / AG Schmitz},
ddc = {150},
cid = {I:(DE-2719)1810003 / I:(DE-2719)1810004},
pnm = {353 - Clinical and Health Care Research (POF4-353) / 351 -
Brain Function (POF4-351)},
pid = {G:(DE-HGF)POF4-353 / G:(DE-HGF)POF4-351},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:40803454},
doi = {10.1016/j.bbi.2025.106073},
url = {https://pub.dzne.de/record/280960},
}